ArticleThe Journal of experimental medicine2001
CD8(+) T cell-mediated injury in vivo progresses in the absence of effector T cells.
Article in The Journal of experimental medicine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 82 citations in OpenAlex.
- CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis.Respiratory research · 2005Trial
- ZBP1-driven cell death in severe influenza.Trends in microbiology · 2025Review
- Regulation of PEST-containing nuclear proteins in cancer cells: implications for cancer biology and therapy.Frontiers in oncology · 2025Review
- Opportunities and challenges for T cell-based influenza vaccines.Nature reviews. Immunology · 2024Review
- Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID.Archives of microbiology · 2023Review
- Comparisons of lymphocytes profiles and inflammatory cytokines levels in blood of patients with differed severity of infection by human adenovirus type 7.BMC infectious diseases · 2023Article
- Behavioral and Dietary Habits That Could Influence Both COVID-19 and Non-Communicable Civilization Disease Prevention-What Have We Learned Up to Now?Medicina (Kaunas, Lithuania) · 2022Review
- Faster cytotoxicity with age: Increased perforin and granzyme levels in cytotoxic CD8Aging cell · 2022Article
- Fungal Infections Other Than Invasive Aspergillosis in COVID-19 Patients.Journal of fungi (Basel, Switzerland) · 2022Review
- Role of Vitamin A Supplementation in Prevention and Control of Coronavirus Disease-19: A Narrative Review.International journal of preventive medicine · 2022Review
- COVID-19 in Ophthalmology. Current Disease Status and Challenges during Clinical Practice.Maedica · 2021Article
- ChronicAmerican journal of physiology. Heart and circulatory physiology · 2021Article
- Therapeutic opportunities of edible antiviral plants for COVID-19.Molecular and cellular biochemistry · 2021Review
- Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management.Heliyon · 2021Review
- Macrophages Inhibit Ciliary Protein Levels by Secreting BMP-2 Leading to Airway Epithelial Remodeling Under Cigarette Smoke Exposure.Frontiers in molecular biosciences · 2021Article
- Dysregulation of the Immune Environment in the Airways During HIV Infection.Frontiers in immunology · 2021Article
- Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy.International journal of medical sciences · 2021Review
- SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2020Review
- A case of coronavirus disease 2019 in acquired immunodeficiency syndrome patient: a case report and review of the literature.Intractable & rare diseases research · 2020Article
- COVID-19 pathophysiology: A review.Clinical immunology (Orlando, Fla.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Tissue injury is a common sequela of acute virus infection localized to a specific organ such as the lung. Tissue injury is an immediate consequence of infection with lytic viruses. It can also result from the direct destruction of infected cells by effector CD8(+) T lymphocytes and indirectly through the action of the T cell-derived proinflammatory cytokines and recruited inflammatory cells on infected and uninfected tissue. We have examined CD8(+) T cell-mediated pulmonary injury in a transgenic model in which adoptively transferred, virus-specific cytotoxic T lymphocytes (CTLs) produce lethal, progressive pulmonary injury in recipient mice expressing the viral target transgene exclusively in the lungs. We have found that over the 4-5 day course of the development of lethal pulmonary injury, the effector CTLs, while necessary for the induction of injury, are present only transiently (24-48 h) in the lung. We provide evidence that the target of the antiviral CD8(+) T cells, the transgene expressing type II alveolar cells, are not immediately destroyed by the effector T cells. Rather, after T cell-target interaction, the type II alveolar cells are stimulated to produce the chemokine monocyte chemoattractant protein 1. These results reinforce the concept that, in vivo, the cellular targets of specific CTLs may participate directly in the development of progressive tissue injury by activating in response to interaction with the T cells and producing proinflammatory mediators without sustained in vivo activation of CD8(+) T cell effectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.